Delavirdine Mesylate Articles

Pharmacia pilots plan for Rescriptor in LDCs

3 February 2003

Pharmacia grants access to HIV drug

3 February 2003

Agouron licenses P&U's Rescriptor

28 October 1999

New product line up at Pharmacia & Upjohn

16 April 1999

First Approval Of DuPont's Sustiva In USA

21 September 1998

Agouron Shopping For HIV Portfolio

1 July 1998

P&U Suspends Rescriptor Trial

5 February 1998

Global Anti-HIV Market To Top $5 Billion In 2005

21 January 1998

1997: Another Good Year For New Chemical Entities

6 January 1998

1998 - A "Critical" Year For P&U, Says CEO

3 December 1997

First Launch For P&U's Edronax

31 July 1997

First Launch Of P&U's Delavirdine In USA

26 June 1997

First Approval For Delavirdine NNRTI

7 April 1997

Gilead's Vistide Cleared By CPMP

6 January 1997

P&U Completes Trials With Tolterodine

16 December 1996

Split Verdict From Panel On P&U's Delavirdine

2 December 1996

Delavirdine Filed In USA; NNRTI Role Reviewed

29 July 1996

P&U Moves To Revamp Inherited Pipeline

3 June 1996

Expanded Access For Delavirdine

15 April 1996

EUROPEAN STOCK COMMENT

29 January 1996

Delavirdine Studies Validate HIV Surrogate Marker Data

22 January 1996

Marriage Of Pharmacia And Upjohn Will Create New $13 Bill Drug Group

4 September 1995

Two More Launches For Upjohn's Freedox

24 April 1995

UPJOHN OUTLINES STRATEGY FOR GROWTH

30 May 1994

UPJOHN OUTLINES STRATEGIC DIRECTIONS

18 April 1994

INCREASE IN NEW AIDS drugs IN TRIALS IN USA FOR 1993

10 January 1994

Showing 1-26 of 26 articles

Go to beginningPrevious
  • 1
NextGo to end